Skip to main content

Table 1 Baseline characteristics of IPF Patients

From: Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data

  IPF Cohort
(N= 4,716)
IPF Diagnostic Testing Subgroup
(N= 2,518)
Age (continuous, years)
 Median, IQR 77.5 72.0 - 82.0 77.0 71.0 - 81.0
 Mean, SD 76.8 5.9 76.3 5.8
Length of Health Plan Membership Prior to Cohort Entry (continuous, months)
 Median, IQR 34.3 21.5 - 58.6 34.7 21.6 - 59.1
 Mean, SD 47.6 37.9 48.1 38.4
  N % N %
Age (years)
 65 – 74 1,683 35.7 981 39.0
 75 – 84 2,633 55.8 1,366 54.2
 85 +a 400 8.5 171 6.8
Sex
 Male 2,374 50.3 1,319 52.4
 Female 2,342 49.7 1,199 47.6
Geographic Area
 Northeast 821 17.4 467 18.5
 Midwest 1,665 35.3 909 36.1
 South 1,776 37.7 911 36.2
 West 454 9.6 231 9.2
Race
 White 3,496 74.1 1,899 75.4
 African American 489 10.4 234 9.3
 Hispanic/Latino 302 6.4 170 6.8
 Asian 113 2.4 49 1.9
 Other 316 6.7 166 6.6
Cohort Entry Period N % N %
 2008 - 2009 970 20.6 525 20.8
 2010 - 2011 1,401 29.7 731 29.0
 2012 - 2014 2,345 49.7 1,262 50.1
Patients with at Least One     
Diagnosis, Procedure, or     
Dispensing for each of the     
Following During the 12-Month Baseline Period:     
 Any Corticosteroid 1,577 33.4 952 37.8
 NAC 40 0.8 24 1.0
 Azathioprine 27 0.6 15 0.6
 Cyclophosphamide 13 0.3 11 0.4
 Open Lung Biopsies 22 0.5 22 0.9
 Oxygen Therapy 1,093 23.2 654 26.0
 GERD Therapy 1,645 34.9 912 36.2
 Anticoagulation/Antiplatelet Therapy 1,346 28.5 781 31.0
 Amiodarone 172 3.6 107 4.2
 Bleomycin 2 0.0 2 0.1
 Nitrofurantoin 207 4.4 95 3.8
 Methotrexate 15 0.3 8 0.3
 Gold Salts 0 0.0 0 0.0
 Epstein-Barr Virus 9 0.2 7 0.3
 Hepatitis C 105 2.2 73 2.9
 Bronchial Lavage 150 3.2 139 5.5
  1. Optum Research Database - Medicare Advantage Population. Cohort Entry: 01 January 2008 - 30 September 2014
  2. Abbreviations: IPF idiopathic pulmonary fibrosis, NAC N-acetyl cysteine, IQR interquartile range, SD standard deviation, GERD gastroesophageal reflux disease
  3. aFor privacy reasons, the earliest year of birth in the MAPD is coded as 1927, so no patients in the cohort entry period prior to 2011 can be coded as age >= 85. Counts for patients who entered the cohort before October 2011 and whose actual age is >= 85 are collapsed into the 75-84 year grouping in this report